SCHEMBL1348165

SCHEMBL1348165

O=C(O)CCC/C=C\C[C@H]1C(=O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCCc1cc2ccccc2s1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 9/20 0.63
PTGER3 P43115 5/20 0.63
PTGFR P43088 5/20 0.63
PTGER1 P34995 3/20 0.63
PTGER2 P43116 2/20 0.63
PTGIR P43119 2/20 0.63
NR1I2 O75469 1/20 0.63
ESR1 P03372 1/20 0.63
PGR P06401 1/20 0.63
HPGD P15428 1/20 0.63
TSHR P16473 1/20 0.63
TBXA2R P21731 1/20 0.63
MAPK1 P28482 1/20 0.63
OPRK1 P41145 1/20 0.63
PDE4D Q08499 1/20 0.63
MGLL Q99685 1/20 0.56
MEN1 O00255 1/20 0.49
THRB P10828 1/20 0.49
KMT2A Q03164 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1348171 1.00 PTGER4 (0.63) PTGER4PTGER3PTGFRPTGER1PTGER2
SCHEMBL1348173 1.00 PTGER4 (0.63) PTGER4PTGER3PTGFRPTGER1PTGER2
SCHEMBL127623 0.96 PTGER3 (0.63) PTGER4PTGER3PTGFRPTGER1PTGER2
SCHEMBL127621 0.96 PTGER3 (0.63) PTGER4PTGER3PTGFRPTGER1PTGER2
SCHEMBL127622 0.96 PTGER3 (0.63) PTGER4PTGER3PTGFRPTGER1PTGER2
SCHEMBL1348136 0.87 PTGDR2 (0.63) PTGER4PTGER3PTGFRPTGER1PTGER2
SCHEMBL1348138 0.87 PTGDR2 (0.63) PTGER4PTGER3PTGFRPTGER1PTGER2
SCHEMBL1348133 0.87 PTGDR2 (0.63) PTGER4PTGER3PTGFRPTGER1PTGER2
SCHEMBL1347773 0.86 PTGER3 (0.62) PTGER4PTGER3PTGFRPTGER1PTGER2
SCHEMBL1347777 0.86 PTGER3 (0.62) PTGER4PTGER3PTGFRPTGER1PTGER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063240-B2 Prostaglandin E1 and E2 analogs for the treatment of various medical conditions CAYMAN CHEMICAL COMPANY, INCORPORATED (US) 2011-11-22 US disclosed
US-20090221654-A1 PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS CAYMAN CHEMICAL COMPANY (US) 2009-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221654-A1 PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS PTGER1, PTGER4, PTGER2 PTGER4 2/4885PTGER3 5/4885PTGFR 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.